Alnylam vs. Ionis: Here's the Better Bad-News Buy

Alnylam reported latest-quarter revenue up 74% year over year to $1.17 billion and adjusted earnings of $251.8 million, but cut full-year guidance after slower-than-expected Amvuttra sales. Ionis' Q2 2026 revenue fell about 41% to $268 million and it posted a $57 million adjusted loss; its comparison was affected by a 2025 upfront payment, and it also faced two July pipeline setbacks. Analysts' average targets implied roughly 88% upside for Ionis and 61% for Alnylam, while the article's author preferred Alnylam for its risk-reward profile and predicted both stocks could outperform over several years.

Analysis

Prefer ALNY on relative risk-adjusted fundamentals, but treat the recent guidance reset as evidence that commercial execution—not just market growth—needs monitoring. Continued Amvuttra growth does not by itself resolve whether uptake is tracking the company’s revised expectations; the next report’s product-level sales and guidance commentary are the key checks. Pfizer’s longer branded runway may support the competitive window, while the eplontersen setback could improve the relative positioning of ALNY’s nucresiran—only if nucresiran’s own data are compelling. Neither is a substitute for clinical validation.

IONS’ quoted analyst upside is not a catalyst. Its revenue comparison is distorted by a prior-period upfront payment, so the sharper issue is whether partnered setbacks weaken confidence in the broader pipeline or future collaboration economics. Conversely, the setbacks are confined to programs, not proof that the entire platform has failed. The contrarian risk in favoring ALNY is that its stronger reported financials may already be reflected in valuation, while the guidance cut signals less predictable product demand.

Near term, biotech sentiment and trial headlines can dominate both stocks. Over 1–3 months, watch ALNY’s next product-sales update and any nucresiran data/timing; over 6–18 months, clinical execution and durability of commercial growth matter more than analyst targets. No valuation or current-price data are supplied, so avoid asserting either stock is cheap or assigning price targets.

Key Decisions for Investors

• Relative-value watch: consider a modest long ALNY / short IONS pair only after checking current valuation, borrow, and biotech-beta exposure; the thesis is ALNY’s stronger commercial footing versus IONS’ greater pipeline and partnership uncertainty, not a claim that IONS’ revenue decline is wholly operational.
• For a directional ALNY entry, scale in around the next earnings update rather than chasing a rebound. Add only if product-level Amvuttra sales and forward guidance support stabilization; reduce or exit if sales miss the revised trajectory again or guidance is cut further.
• Treat nucresiran as a catalyst watch, not an established beneficiary of eplontersen’s failure. Reassess on trial design, timing, and efficacy data; disappointing or delayed evidence would weaken the relative thesis.
• Do not use analyst price targets as a standalone buy signal for IONS. Revisit the short leg if Ionis demonstrates progress in unaffected programs or secures replacement partner economics; those developments could invalidate the relative underperformance thesis.